Construction and application of a mammalian model of pulmonary fibrosis

Abstract

The invention belongs to the field of experimental zoology and provides the application of polyhexamethylene monoguanidine or polyhexamethylene biguanide in establishing a mammalian model of pulmonary fibrosis. The present invention also provides a method for constructing a mammalian model of pulmonary fibrosis, which includes the following steps: exposing the mammal to an environment containing polyhexamethylene monoguanidine or polyhexamethylene biguanide, polyhexamethylene The inhaled amount of methyl monoguanide or polyhexamethylene biguanide is 10% of the mammalian body weight ‑8 ~10 ‑6 and continue feeding for 20-40 days to obtain the mammalian model of pulmonary fibrosis. The present invention also provides the application of the pulmonary fibrosis mammalian model obtained by the above method in the study of the pathogenesis of pulmonary fibrosis and therapeutic drugs.

Description

technical field

[0001] The invention belongs to the field of experimental zoology, and in particular relates to the application and method of a cationic guanidine polymer compound in establishing a mammalian model of pulmonary fibrosis. Background technique

[0002] Pulmonary fibrosis is a major respiratory disease that affects human health, and its etiology has not yet been fully studied. Clinically, drugs for the treatment of pulmonary fibrosis can only alleviate the process of pulmonary fibrosis, but cannot cure this type of disease. Medical-assisted treatment can prolong the life of patients to a certain extent, but the radical cure of pulmonary fibrosis requires in-depth research on its pathogenesis to find specific drugs for treatment. The pathogenesis of pulmonary fibrosis and the development of effective intervention methods are current research hotspots. Therefore, it is necessary to simulate the process of pulmonary fibrosis in clinical patients in vitro, so as to...

Examples

Embodiment 1

[0020] Using 4-week-old mice of the C57BL / 6N strain, use an ultrasonic nebulizer to ultrasonically nebulize 1 mg / mL polyhexamethylene monoguanidine solution, and the concentration in the exposure box is about 10 mg / m 3 , the mice were exposed for 4 hours, once every other day, for three consecutive exposures.

[0021] After raising the mice for one month, the mice were dissected pathologically, and the lung tissue was stained with hematoxylin-eosin to observe the fibrosis lesions of the lung tissue. It was found that the lung tissue had fibrosis-like changes, the alveolar wall was thickened, and the alveolar collapsed. , uneven distribution, a large number of inflammatory cell infiltration, consistent clinical symptoms of pulmonary fibrosis.

Embodiment 2

[0023] Using 4-week-old Balb / c strain mice, inject 0.1 mL of 2 mg / mL polyhexamethylene biguanide solution into the airways of the mice using a tracheal infusion needle, inject once, and raise the mice for one month. The mice were dissected, and the collagen deposition in the lung tissue was observed using Masson's trichrome staining technique. It was found that there was obvious collagen deposition in the lung tissue, indicating that pulmonary fibrosis lesions appeared in the lungs of the mice.

Embodiment 3

[0025] Using 8-week-old SD rats, inject 0.2 mL of 3 mg / mL polyhexamethylene biguanide solution into the airway of the rats with a tracheal infusion needle, inject once, and after feeding the rats for one month, dissect the rats , using a-SMA antibody to stain the lung tissue of rats, observe the expression of lung tissue fibrosis markers, and find that the lung tissue fibrosis marker a-SMA is significantly expressed, indicating that pulmonary fibrosis lesions appear in the lungs of rats, the model The build was successful.

technical field

[0001] The invention belongs to the field of experimental zoology, and in particular relates to the application and method of a cationic guanidine polymer compound in establishing a mammalian model of pulmonary fibrosis. Background technique

[0002] Pulmonary fibrosis is a major respiratory disease that affects human health, and its etiology has not yet been fully studied. Clinically, drugs for the treatment of pulmonary fibrosis can only alleviate the process of pulmonary fibrosis, but cannot cure this type of disease. Medical-assisted treatment can prolong the life of patients to a certain extent, but the radical cure of pulmonary fibrosis requires in-depth research on its pathogenesis to find specific drugs for treatment. The pathogenesis of pulmonary fibrosis and the development of effective intervention methods are current research hotspots. Therefore, it is necessary to simulate the process of pulmonary fibrosis in clinical patients in vitro, so as to...

Examples

Embodiment 1

[0020] Using 4-week-old mice of the C57BL / 6N strain, use an ultrasonic nebulizer to ultrasonically nebulize 1 mg / mL polyhexamethylene monoguanidine solution, and the concentration in the exposure box is about 10 mg / m 3 , the mice were exposed for 4 hours, once every other day, for three consecutive exposures.

[0021] After raising the mice for one month, the mice were dissected pathologically, and the lung tissue was stained with hematoxylin-eosin to observe the fibrosis lesions of the lung tissue. It was found that the lung tissue had fibrosis-like changes, the alveolar wall was thickened, and the alveolar collapsed. , uneven distribution, a large number of inflammatory cell infiltration, consistent clinical symptoms of pulmonary fibrosis.

Embodiment 2

[0023] Using 4-week-old Balb / c strain mice, inject 0.1 mL of 2 mg / mL polyhexamethylene biguanide solution into the airways of the mice using a tracheal infusion needle, inject once, and raise the mice for one month. The mice were dissected, and the collagen deposition in the lung tissue was observed using Masson's trichrome staining technique. It was found that there was obvious collagen deposition in the lung tissue, indicating that pulmonary fibrosis lesions appeared in the lungs of the mice.

Embodiment 3

[0025] Using 8-week-old SD rats, inject 0.2 mL of 3 mg / mL polyhexamethylene biguanide solution into the airway of the rats with a tracheal infusion needle, inject once, and after feeding the rats for one month, dissect the rats , using a-SMA antibody to stain the lung tissue of rats, observe the expression of lung tissue fibrosis markers, and find that the lung tissue fibrosis marker a-SMA is significantly expressed, indicating that pulmonary fibrosis lesions appear in the lungs of rats, the model The build was successful.

Images